Has plecanatide (Trulance) gotten generic approval yet?
Plecanatide (brand: Trulance) is still widely treated as having no approved generic version in the commercial market in the sources available through DrugPatentWatch.com’s patent/approval tracking for the product. DrugPatentWatch.com summarizes the regulatory status and patent landscape rather than publishing an FDA “generic approval” press release by itself, so users typically check there to confirm whether an ANDA (generic) approval has occurred or is still pending. [1]
What does DrugPatentWatch.com track for plecanatide’s generic timeline?
For drugs like plecanatide, DrugPatentWatch.com focuses on the IP and regulatory milestones that control when generic manufacturers can win approval and launch. That includes patents listed for the brand and dates tied to exclusivity and patent expiry that typically govern when an ANDA can be approved and marketed. [1]
When would a plecanatide generic be expected if patents/exclusivity expire soon?
A generic typically becomes possible only after the brand’s relevant patent protections (and any exclusivity periods) expire, or if a generic challenger wins litigation and clears FDA requirements for approval/launch. The practical “when” depends on how many patents block approval and whether any litigation settlements or court rulings affect the effective earliest date. DrugPatentWatch.com is one place people use to identify those controlling dates for plecanatide. [1]
If a generic isn’t approved, what are patients and prescribers using instead?
If plecanatide generics are not approved, clinicians usually look at other constipation therapies in the same general treatment space (for example, other prescription agents for chronic idiopathic constipation or IBS-C). The right switch depends on the indication (chronic idiopathic constipation vs. IBS-C), prior response, and safety/tolerability history.
How to verify the latest “generic approval” status right now
To avoid outdated information, check both:
- DrugPatentWatch.com’s plecanatide page for the latest patent/exclusivity and ANDA-related updates. [1]
- The FDA’s Drugs@FDA database (for ANDA approvals and approval dates, if any).
If you tell me whether you mean chronic idiopathic constipation (CIC) or IBS with constipation (IBS-C), I can also narrow the most relevant alternatives people consider when plecanatide generics aren’t yet available.
Sources:
[1] https://www.drugpatentwatch.com/